MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03711nam a22004575i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
TR-AnTOB |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20231109085746.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
221118s2022 sz | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783031113635 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-3-031-11363-5 |
| Source of number or code |
doi |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
TR-AnTOB |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
TR-AnTOB |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
İngilizce |
| 060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
WC 100 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJ |
| Source |
bicssc |
|
|---|
| Subject category code |
MED045000 |
| Source |
bisacsh |
|
|---|
| Subject category code |
MJ |
| Source |
thema |
| 096 ## - LOCALLY ASSIGNED NLM-TYPE CALL NUMBER (OCLC) |
|---|
| Classification number |
WC100EBK |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Infectious Complications in Biologic and Targeted Therapies |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Carlos Cervera, Jose Maria Aguado. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st ed. 2022. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Cham : |
| Name of producer, publisher, distributor, manufacturer |
Springer International Publishing : |
| -- |
Imprint: Springer, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Overview on the risk of infection associated with biologic and targeted therapies -- Timeline of infections associated with biologic and targeted therapies -- Infectious disease evaluation of candidates to new therapies -- Vaccines and biologic and targeted therapies -- Travel and risk of infections -- Anti-necrosis tumoral factor-alpha agents -- CD19-targeted agents -- CD20-targeted agents -- CD22-targeted agents -- CD30-targeted agents -- CD33 and CD38-targeted agents -- CD40 and CD319-targeted agents -- CD52-targeted agents -- CCR4-targeted agents -- Cell-surface receptors I: VEFG targeted agents -- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents -- Interleukin-1 targeted agents -- Interleukin-5 and interleukin-6 targeted agents -- Interleukin-12/23 p40 targeted agents -- Sphingosine-1 phosphate receptor modulators -- Immune checkpoint inhibitors -- α4-integrin-targeted agents -- Tyrosin-kinase inhibitors -- Bcl-2, JAK and mTOR inhibitors -- Infections associated with the use of CarT cells -- Pulmonary infiltrates -- Tuberculosis -- Cytomegalovirus and other herpesviruses -- Invasive fungal infections -- Progressive multifocal leukoencephalopathy -- Hepatitis virus. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Internal medicine. |
|
|---|
| Topical term or geographic name entry element |
Internal Medicine. |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Communicable Diseases -- drug therapy |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Cervera, Carlos. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
|
|---|
| Personal name |
Aguado, Jose Maria. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://doi.org/10.1007/978-3-031-11363-5">https://doi.org/10.1007/978-3-031-11363-5</a> |
| Materials specified |
Springer eBooks |
| Public note |
Online access link to the resource |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
National Library of Medicine |
| Koha item type |
E-Book |
